First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Stock Market Shrugs; Biotechs Rise Slightly
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.
